ASCO GI 2024 | Maria-Colorectal Cancer Observational trial: MRD assay for recurrence and response

Edward D. Esplin, MD, PhD, Invitae, San Francisco, CA, talks on the MARIA study (NCT05219734), which aims to assess the potential of the Invitae Personalized MonitoringTM (PCM) test as a highly sensitive tumor-informed molecular residual disease (MRD) test for patients monitoring early-stage colorectal cancer (CRC). The study involves 200 newly diagnosed patients with early-stage CRC undergoing curative intent treatment. The PCM test utilizes formalin-fixed paraffin-embedded tissue to create a patient-specific panel for circulating tumor DNA (ctDNA) analysis. The primary endpoint is to evaluate the correlation between the PCM test result at the landmark timepoint and the patient’s 24-month recurrence risk. Secondary endpoints include assessing the impact on patient outcomes, correlating PCM results with recurrence risk, and investigating the lead time of PCM positivity over clinical/imaging-based evidence of recurrence. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.